We observed the expression and chromatin accessibility of PDCD1 and CXCR4 increased in T‐ALL cells post‐treatment, suggesting PDCD1 and CXCR4 inhibitors may be considered to be used for against refractory T‐ALL. This evidence concerns the gene CXCR4 and acute lymphoblastic leukemia.